The power of the Global Drug Policy Index lies in its key objective: to score and
rank how countries are faring in different areas of drug policy as identified in the
UN report ‘What we have learned over the last ten years: A summary of knowledge
acquired and produced by the UN system on drug-r...elated matters’,1 and derived
from the landmark UN System Common Position on Drug
more
Advocacy achievements of the bridging the gaps global partners
Accessed: 17.11.2019
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
2016 data
The report was coordinated by Anastasia Pharris and Annemarie Stengaard.
Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... Rondy, Chantal Quintin, Phillip Zucs.
more
Handbook of HUMANITARIAN HEALTH CARE LOGISTICS Designing the Supply Network and Managing the Flows of Information and Health Care Goods in Humanitarian Assistance during Complex Political Emergencies
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Teymur Noori, with technical support from Andrew J. Amato-Gauci, Anastasia Pharris, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
Noncommunicable diseases (NCDs) such as cancer, cardiovascular disease, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kazakhstan. This report provides evidence through three analyses that NCDs reduce economic output and ...discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs (direct and indirect costs) comprise 2.3 trillion tenge, equivalent to 4.5% of gross domestic product in 2017. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment. For example, the salt policy package achieved a benefit-to-cost ratio of 118.4 over 15 years, a return of more than 118 tenge for every 1 tenge invested.
more
There are two sets of charts. One set (14 charts) can be used in settings where blood cholesterol can be measured. The other set (14 charts) is for settings in which blood cholesterol cannot be measured. Both sets are available in colour and shades of black on a compact disc. Each chart can only be ...used in countries of the specific WHO epidemiological sub-region
more
Public health Panoram, Vol.2 Issue 1 March 2016
Joint Press Release
Stockholm/Copenhagen 20/03/2017
Public Health Factsheet
Accessed: 29.09.2019
Medicina (Kaunas) 2013;49(7):335-40
Vinay P. Saldanha( UNAIDS Regional Director- Eastern Europe & Central Asia)
Session 1 Wednesday 30/01/2019
30-31 January 2019, Bucharest
Accessed: 29.09.2019